Roche Zen Horizon Framework Deep Dive: A Diagnostics and Pharma Giant Past the Patent Cliff, with a Fair Price and Debated Growth

II. Longitudinal History: From a Basel Vitamin Workshop to a Biopharmaceutical Empire That Bought Genentech

2.1 Origin: A 28-Year-Old Founder and the Idea of Turning Medicine into Standardized Products

Roche was founded in Basel in October 1896 by Fritz Hoffmann-La Roche. Its predecessor was Hoffmann, Traub & Co. in 1894, renamed after partner Traub exited in 1896. Fritz's judgment was forward-looking for the time: while others were still selling hand-compounded herbal medicines, he bet that industrialized, standardized, and branded pharmaceuticals would become the infrastructure of modern medicine. The "La Roche" in the company name came from the surname of his wife, Adele La Roche. That family name still determines control of the company 130 years later.

Early Roche started with vitamins and was once the world's largest vitamin producer. After World War II, it gradually shifted to prescription drugs and earned its first major profit pool in psychiatric medicines, including Valium. Most of its early rivals have been folded into today's giants such as Novartis and Sanofi, while Roche has remained independent through family control and long-termism.

2.2-2.4 Three Stages That Determined Its Fate

Stage 1: The bet from chemical drugs to biologics (1990-2009). The most important thing Roche got right was raising its stake in U.S. biotechnology pioneer Genentech starting in 1990. When most large pharmaceutical companies still treated biologics as peripheral, Roche concluded that monoclonal antibodies were the future. Genentech gave it Rituxan, Herceptin, and Avastin, three "money printers" that pushed Roche to the top of global oncology. In 2009, Roche paid USD 95 per share, or about USD 46.8 billion in total, to acquire all publicly held Genentech shares it did not already own. It already held about 56%, and financed about USD 39.0 billion in the bond market. This was the largest and most successful capital allocation in Roche's history. Genentech remains its U.S. innovation engine.

Stage 2: The golden age of the three major oncology drugs and the patent cliff (2010-2022). Throughout the 2010s, Avastin, Herceptin, and Rituxan (called MabThera in Europe) supported Roche's high growth and high profits. But patent expiry for all three cards approached at nearly the same time. From 2019 onward, biosimilars launched across the U.S., Europe, and Japan, beginning a severe erosion. In 2020 alone, the three major drugs lost about CHF 5.0 billion, or about USD 5.6 billion, to biosimilars, with U.S. Avastin, Rituxan, and Herceptin down 37%, 32%, and 47% respectively in that year. Company executives acknowledged that this would leave an approximately USD 10 billion sales gap for new drugs to fill. This is the first key to understanding Roche over the past six years: it first went through a self-created and foreseeable major blood loss.

Stage 3: Filling the gap, clearing COVID, changing CEO, and betting on obesity (2022-present). The key fact in this stage is repair. On one hand, the COVID-testing boom and bust cleared out. COVID-related diagnostics revenue fell from a 2021 peak of CHF 4.7 billion to CHF 4.1 billion in 2022, only CHF 400 million in H1 2023, and essentially zero by 2024. On the other hand, next-generation drugs successfully took over. In 2023, the group completed a CEO transition: former diagnostics head Thomas Schinecker became CEO, while former CEO Severin Schwan became chairman. From 2023 to 2025, Roche made intensive bolt-on acquisitions to replenish the pipeline, with the headline move being its late entry into obesity drugs (see Sections V and VIII). One capital-market event that is easy to overlook but important was the late-2021 repurchase and cancellation of Novartis's Roche registered shares for about USD 20.7 billion, which sharply increased the family pool's voting-share percentage (see governance in Section V).

III. Longitudinal Financial Review: Strong Underlying Performance, Mediocre Reporting, Because the Strong Swiss Franc Ate Everything

To read Roche's financials, one must first distinguish two sets of metrics. Otherwise, the conclusions become completely different:

• Core metrics (core, Roche's preferred presentation): exclude acquisition amortization, impairments, and major legal/restructuring items, reflecting underlying operations. In 2025, core operating profit was CHF 21.833 billion, core operating margin about 35.5%, and core diluted EPS CHF 19.46.

• IFRS reported metrics (commonly used by third parties): 2025 IFRS net income was CHF 13.799 billion. The PE-TTM calculated by third parties on this basis was about 20x.

The two differ by about 6 percentage points in margin and should not be mixed.

Over the past decade, three business facts matter much more than the numbers themselves:

First, the underlying business is accelerating, but reported figures are being eaten by the strong Swiss franc. This is Roche's core financial contradiction today. In both 2024 and 2025, constant-currency sales grew +7%, but reported Swiss-franc growth was only +3% and +2%. Currency was a 5 percentage-point drag in 2025. The profit side was even harsher: core operating profit grew +13% at constant currency but only +5% in CHF, an 8 percentage-point currency hit. In Q1 2026, released on 2026-04-23, sales were CHF 14.7 billion, +6% at constant currency and -5% reported, with a single-quarter currency hit of CHF 1.6 billion. Roche's costs are in the Swiss-franc zone while revenue is in U.S. dollars and euros. A strong Swiss franc is a long-term structural erosion of reported numbers, which is why a "reaccelerating" company can appear to have almost no reported revenue growth.

Second, new drugs have already filled the patent-cliff hole. The top five growth drugs generated CHF 21.4 billion in 2025 and increased by CHF 3.2 billion year over year, while the patent-expired portfolio (Avastin/Herceptin/Rituxan/Lucentis/Actemra and others) was only down 4%, a reduction of about CHF 700 million to CHF 1.0 billion in 2025. The incremental contribution from new drugs is already several times the loss from older drugs, which is the underlying reason the group recovered to +7% constant-currency growth and the hard evidence behind the turnaround narrative.

Third, cash quality and the balance sheet are solid, which is Roche's foundation. In 2025, operating free cash flow was CHF 16.2 billion and free cash flow was CHF 11.8 billion, down year over year due to large acquisitions and currency drag. Net debt was about CHF 16.2 billion at year-end 2025, continuing to decline from CHF 17.3 billion in 2024. The capital-allocation profile is clear: high dividends, aggressive bolt-on pipeline replenishment, and almost no market-cap-management-style buybacks. The dividend is its strongest badge. Roche has raised its dividend for about 39 consecutive years, pending approval of CHF 9.80 at the March 2026 shareholder meeting, making it a rare European dividend aristocrat. But dividend growth over the past three years has slowed to about 1-2% per year.

IV. Share Price and Valuation History: Structurally a "Market Multiple" Pharma Stock, Now Toward the Low End of History

Roche has never been a high-multiple stock, nor a deep value stock. It has long been a large-cap defensive stock that receives roughly a market-average multiple and earns its keep through high dividends and certainty. A review of capital-market history:

• It peaked at CHF 439 in April 2022, the dual high point of COVID-testing tailwinds and defensive capital seeking shelter.

• It then drifted down over the next three years and bottomed in the CHF 230-260 range in 2024-2025, hit by the patent cliff, COVID-testing decline, strong Swiss franc, and pipeline setbacks. The 52-week range was about CHF 232-375.

• In 2025, obesity-pipeline data plus reaccelerating growth drove a rebound of more than 30%. The current participation certificate price is about CHF 322 (2026-06-03), while registered share RO is about CHF 331 (2026-06-04), still about 27% below the 2022 high.

Current valuation, using the participation certificate price of about CHF 322: core PE about 16.5x (CHF 322 divided by core EPS 19.46), IFRS PE-TTM about 20x, forward PE about 16x, EV/EBITDA about 11.5x, and dividend yield about 3.0% (9.80 divided by 322). Among large pharmaceutical companies, this set of numbers is on the low side and clearly not expensive. It reflects market skepticism about growth, and also means downside has already been priced out to a meaningful degree. The valuation center has moved down in recent years because market preferences and growth expectations changed, not because business quality collapsed.

V. Business Model and Moat: The Diagnostics River Is Deepest, the Pharmaceutical River Is Changing Water

5.1-5.2 Revenue Structure and Operating Leverage

Roche has two major divisions. Pharmaceuticals, about 77.5% of revenue, has extremely high gross margin and profit margin. The pharmaceutical core margin in H1 2025 was about 52%, making it the main profit engine. Diagnostics, about 22.5% of revenue, has a much lower margin, about 18%, and was dragged down in 2025 by China's diagnostics volume-based procurement (VBP), with reported revenue down 3%. The group core operating margin of about 35.5% is the blended figure after diagnostics dilutes it. On operating leverage, pharmaceuticals' high fixed R&D spending, with group R&D of about CHF 12.2 billion, about 19% of revenue, makes profit sensitive to sales volatility.

5.3 Moat: Which Ones Really Hold

1. Scale, installed base, and reagent loop in in vitro diagnostics, the deepest moat. Roche Diagnostics is global No. 1 in IVD, with 2023 diagnostics revenue of about USD 16.8 billion, firmly leading the top four. Its moat is the classic razor-and-blade model: install analyzers in hospital laboratories worldwide, then charge recurring revenue for proprietary reagents, layered with regulatory certification and clinical switching costs. This is Roche's most stable and hardest-to-disrupt moat.

2. The "diagnostics + treatment" synergy and companion diagnostics in pharmaceuticals. Roche can use its own diagnostics to support companion diagnostics for its own medicines, such as HER2 testing paired with Herceptin/Phesgo. This creates a closed loop of "test first, treat next," a structural advantage that pure pharmaceutical companies or pure diagnostics companies do not have.

3. Next-generation franchises in neurology, hematology, and ophthalmology. Ocrevus (MS), Hemlibra (hemophilia), and Vabysmo (retinal disease) are benchmark drugs in their fields, with longer patent lives and high clinical barriers.

But it is important to be honest: the pharmaceutical river is changing water. The old oncology moat built on Avastin, Herceptin, and Rituxan has largely been broken by biosimilars. In the largest immuno-oncology segment, PD-1/PD-L1, Roche's Tecentriq generated only CHF 3.56 billion in 2025, far behind Merck's Keytruda at about USD 31.7 billion, and even lost share to Keytruda in indications such as bladder cancer. The moat still exists, but the pharmaceutical side is a dynamic balance of an old river drying up and a new river taking shape, not a static wide moat.

5.4 Management and Governance: Smooth Transition, but the Family Uses 8.6% Economic Ownership to Lock Up 65% of Voting Rights

Roche's governance is its most distinctive and controversial feature:

• Dual-class capital structure plus family pool control. Roche has 106,691,000 voting registered shares (ticker RO) and 702,562,700 non-voting participation certificates (ticker ROP, formerly Genussschein/ROG). Through a pool agreement established in 1948, the Hoffmann/Oeri families held 64.97% of voting rights as of 2025-12-31. But the pool holds only registered shares and no participation certificates, so its economic interest calculated against all outstanding securities is only about 8.6% [inference: 69,318,000 divided by 809,253,700]. In other words, the family firmly controls about 65% of voting rights with about 8.6% economic ownership, a typical severe mismatch between voting rights and economic ownership.

• Retail holders of participation certificates have no voting rights. The ROG.SW participation certificates held by index funds and retail investors carry no voting rights and no say over board composition or major resolutions. This is a structural governance discount.

• Ticker change in 2026. Participation certificates were converted 1:1 from Genussschein (ROG) into Partizipationsschein (ROP) from 2026-03-17, with unchanged economic rights. This is a technical change, but investors tracking the security should note that the ticker has changed.

• Management and subsidiary. CEO Thomas Schinecker took office in 2023 and has a diagnostics background. Chairman Severin Schwan is the former CEO. CFO Alan Hippe has served since 2011. Roche also controls about 59.89% of the share capital of Japan-listed Chugai Pharmaceutical (4519.TSE), which serves as its Japanese pharmaceutical arm.

The two sides of family control are clear: benefits include long-termism, resistance to hostile takeovers, the family has publicly said "Roche will not be sold," and strategic continuity; costs include concentrated governance, weak minority-shareholder voice, and limited external supervision. This is an almost impossible-to-remove long-term discount on the valuation multiple [View].

VI. Industry and Cycle: A Defensive, High-Quality Field Reshaped by Three Structural Forces

Pharmaceuticals plus diagnostics is a classic low-cyclical, defensive industry. Demand is rigid and has low correlation with the macroeconomy. But Roche's area is being reshaped by three structural forces:

• Patent cliffs and biosimilars: Patent expiry for biologics is a foreseeable cliff, and Roche has just passed the steepest section.

• U.S. drug pricing and tariffs: U.S. IRA drug-price negotiations, where the third IPAY 2028 list includes Xolair, co-promoted by Roche and Novartis, though U.S. Xolair is mainly booked by Novartis and Roche's core drug Ocrevus is not selected, so direct exposure is relatively limited. There is also the Section 232 pharmaceutical tariff that took effect in April 2026: a 100% ad valorem baseline tariff on patented drugs, a 15% Switzerland rate, but companies that have signed MFN pricing agreements can receive 0% tariffs until 2029. Roche's Genentech has signed an MFN agreement with the White House in exchange for a three-year tariff pause, and committed to USD 50.0 billion of U.S. investment over five years as an offset. This substantially mitigates the worst tariff scenario, at the cost of pricing concessions and capital-expenditure pressure.

• The GLP-1 obesity gold rush: This is the largest variable reshaping pharmaceutical valuations today. The market gives obesity leaders such as Eli Lilly a multiple far above mature pharmaceutical companies, while giving late entrants such as Roche an "option" valuation.

In cyclical terms, Roche is almost a non-cyclical defensive stock. Its biggest "cycle" is actually its own patent cycle and pipeline realization cycle, not the macro cycle. Its current position: the steepest phase of the patent cliff is over, and new drugs have successfully taken over in the late stage of recovery.

VII. Horizontal Peers: Valuation Is Mid-Pack Among Mature Pharma, but Looks "Unsexy" Beside the Obesity Leaders

Pharmaceuticals is a highly competitive field. The most representative comparisons are Novartis in the same city, AstraZeneca in the U.K., Merck in the U.S., and obesity leaders Eli Lilly and Novo Nordisk. On the diagnostics side, peers include Abbott, Danaher, and Thermo Fisher.

A horizontal comparison clarifies Roche's true niche: it is a mature giant with mid-pack valuation, moderate growth, and first-class quality, sitting between "cheap with no growth" and "expensive but high growth." Start with valuation. U.S.-listed peers are as of the 2026-06-04 close in USD; Roche is SIX/CHF and slightly earlier, so cross-market and cross-currency comparisons are imperfect:

The conclusion is clear: Roche's forward PE of about 16x is almost identical to Novartis, lower than AstraZeneca and Merck, and far below obesity leader Eli Lilly at 30x forward. This is not a sign of overvaluation. The market is giving Roche neutral pricing for "mature, certain, moderate growth plus high dividend," not a high-growth premium.

One revealing cross-section is the divergence between the two obesity leaders. Eli Lilly enjoys a 40x TTM PE, while Novo Nordisk has only 10.4x because its 2026 guidance implies revenue and profit down 5% to 13%, U.S. price cuts, and loss of exclusivity. In the same obesity field, the valuation gap between the leader and the laggard is huge. This shows precisely that valuation rewards in obesity go only to real winners; for catch-up players such as Roche, the value can only be a discounted option.

In ecosystem terms, Roche is global No. 1 in IVD, its most stable position; large in oncology but behind in immuno-oncology, where Keytruda has taken the flag; and a late catch-up player in obesity, with no marketed product. It fills the unique gap of integrated diagnostics plus treatment. Its most direct targets are the oncology, neurology, and ophthalmology profit pools of other large pharmaceutical companies, while the most likely attackers on its own profit pools are Merck in oncology, Regeneron in ophthalmology with Eylea HD, and Chinese diagnostics manufacturers through IVD VBP.

VIII. Current Fundamentals and Bull-Bear Debate: The Underlying Repair Is Real, the Obesity Option Is a Bet

8.1-8.2 Recent Quarters

For full-year 2025, the group grew +7% at constant currency and pharmaceuticals grew +9% at constant currency, driven by Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo. Q1 2026 sales were CHF 14.7 billion, +6% at constant currency, showing continued underlying growth. The market is now trading two lines: the recovery line of "patent cliff cleared plus new drugs taking over," and the option value of the obesity pipeline.

8.3 Bull-Bear Debate: Everything Rests on "Growth Quality" and "Obesity Value"

Concrete evidence for the bulls: 1. The patent cliff has cleared, new-drug growth is several times old-drug erosion, and the group has returned to +7% constant-currency growth. 2. The global No. 1 diagnostics moat is solid, cash flow is strong, and Roche is nearly a 40-year dividend aristocrat. 3. Valuation is not expensive, at about 16x forward, 3% dividend, and 27% below the high, with downside already priced out. 4. Obesity is a free option: CT-388 has entered Phase III and data are competitive. 5. Next-generation oncology drugs are taking over, including Itovebi approval with peak expectations of about USD 2.3 billion, Columvi, and others.

Concrete evidence for the bears: 1. Reported growth is almost zero because the strong Swiss franc is structurally eating growth, with Q1 2026 reported down 5%. 2. The oncology franchise keeps eroding, and immuno-oncology is being crushed by Keytruda. 3. Obesity is several years late and unproven: CT-388 is injectable, its data match rather than exceed Zepbound, oral CT-996 has a tolerability signal of about 85% nausea, and Eli Lilly/Novo already hold about 70% of the market. 4. The pipeline has suffered repeated setbacks: giredestrant failed a first-line breast-cancer Phase III trial in 2026-03, with the share price down 3% that day, and astegolimab failed a COPD Phase III trial. 5. There is explicit sell-side bearishness: Jefferies downgraded Roche to Underperform on 2025-10-27 with a CHF 230 target price, citing a roughly 10% premium to European peers without growth support, PEG above 2x, and about one-third of 2030 sales exposed to competitive pressure.

The key judgment: the underlying repair is real, supported by new drugs filling the gap and +7% constant-currency growth, but growth is materially offset by the strong Swiss franc and oncology erosion, while the obesity option is more likely a discounted lottery ticket for a follower than a second curve that changes Roche's fate. Roche management has publicly said it aims to be top three in obesity, but "top three" itself admits it is not No. 1.

IX. Valuation Analysis: Fair Price, but No Safety Margin at the Current Level

9.1-9.2 History and Peers

Historical position: the current participation certificate price is about CHF 322, with core PE about 16.5x and forward PE about 16x. This is toward the low end of Roche's own historical band and about 27% below the 2022 high. Peers: forward PE is in line with Novartis, lower than AstraZeneca/Merck, and far below Eli Lilly. This is not an expensive stock. The discipline warning should work in reverse here: one cannot ignore that growth is indeed debated just because "it is not expensive."

9.3 Absolute Valuation: Three Scenarios, Participation Certificate in CHF

Normalized anchors: FY2025 core EPS CHF 19.46, FY2026E about CHF 20.5 as implied by forward PE of about 16x, and dividend CHF 9.80. The three scenarios are:

The current CHF 322 sits below the lower end of the base band (CHF 340) and above the upper end of the bear band (CHF 285). The market is giving Roche a price "slightly below neutral intrinsic value." This means a mild cushion exists, but it is not a thick safety margin. Upside to the base band is about +6% to +19% plus a 3% dividend, while downside to the bear band is about -12% to -22%. Risk-reward is roughly balanced and slightly positive.

9.4-9.5 Safety-Margin Review, Independent Discipline

• The current price is a premium of about 13-29% to the bear scenario of CHF 250-285, meaning there is real downside if the bear case materializes.

• The most fragile assumptions are "obesity can become a meaningful seller" and "oncology erosion remains controlled." If the obesity option goes to zero and oncology losses accelerate, base-case valuation falls into the bear band.

• If core EPS is flat over the next 3 years, the current core PE of about 16.5x corresponds to an earnings yield of about 6%, plus a 3% dividend. That is acceptable for a defensive pharmaceutical company, but it is not a safety margin of clear undervaluation.

• This is a classic good company at a fair price: not expensive, but not cheap enough to provide a thick cushion. It is worth buying more actively at a lower price closer to the bear band, rather than chasing at the current price.

• Conclusion on adequacy of safety margin: not obvious.

X. Risk Analysis

Business risks: 1. Oncology erosion (medium/high): old drugs face biosimilars and immuno-oncology is being crushed by Keytruda. Observable indicators are Tecentriq share and the decline in the old-drug portfolio. 2. Obesity failure (medium/high): CT-388 Phase III failure or weaker-than-expected commercialization would reduce the option to zero. 3. Ophthalmology competition (medium/medium): Vabysmo, about CHF 4.1 billion in 2025, faces a counterattack from Regeneron's Eylea HD. 4. Diagnostics VBP (medium/medium): continued price pressure from China VBP, with Q1 2026 China molecular diagnostics down 7%.

Financial risks: Overall low, with strong FCF and moderate net debt. The main issues are the long-term translation drag from a strong Swiss franc on reported numbers, and goodwill/contingent-consideration impairment risks from bolt-on acquisitions.

Valuation risk (medium): Valuation is already not high, so room for multiple compression is relatively limited. But if the market accepts the Jefferies view of "premium to European peers without growth," forward PE could still compress from 16x to 13x, implying about -18% downside.

Governance and external risks: The mismatch between the family pool's roughly 65% voting rights and 8.6% economic ownership (medium/medium, long-term discount); U.S. drug pricing through MFN concessions and tariffs, mitigated by the signed agreement but with higher capex pressure; and continued Phase III pipeline failures, with recent setbacks including giredestrant, astegolimab, and emugrobart.

XI. Catalysts and Tracking Indicators

Positive catalysts: positive CT-388 Phase III data, launch of obesity combination therapy (CT-388 + petrelintide), stabilization of China diagnostics pressure, scaling of new oncology drugs such as Itovebi/Columvi, a weaker Swiss franc improving reported growth, and continued dividend increases. Negative catalysts: obesity Phase III failure, more Phase III pipeline setbacks, accelerating oncology share loss, deterioration in U.S. drug pricing/tariffs, and continued Swiss-franc strength.

Tracking dashboard (six key items): 1. The gap between group constant-currency and reported growth, to measure Swiss-franc drag; above 5 pct is a structural headwind. 2. Quarterly growth of the top five growth drugs, to see whether new-drug succession continues. 3. Decline in the patent-expired portfolio, to judge whether old-drug loss is controlled. 4. CT-388/CT-996 Phase III milestones and weight-loss data, the survival line for the obesity option. 5. Diagnostics constant-currency growth and China VBP impact, to measure moat monetization. 6. Core operating margin, with 35%+ indicating health. On valuation, track forward PE: above 18x is somewhat expensive, below 14x approaches the bear band and creates a safety margin, and a return below CHF 290 could justify an upgrade.

XII. Horizontal-Vertical Synthesis: A Good Company Past the Cliff, Standing at a Fair Price, Waiting for a Better Entry Point

Longitudinally, what Roche has truly proved is its ability to regenerate through innovation in the face of a foreseeable major blood loss. It rose to the top of oncology early on through Genentech biologics, then filled the hole left by the patent cliff in its three major oncology drugs, an approximately USD 10 billion gap, with next-generation drugs such as Ocrevus, Hemlibra, and Vabysmo, pulling the group back to +7% constant-currency growth. Its diagnostics business is an independent and globally leading deep moat. This is a world-class company that has passed through its hardest test.

But it has also proved that it does not qualify as "high-quality compound growth." Reported growth is persistently eaten by the strong Swiss franc, with Q1 2026 reported down 5%; immuno-oncology has lost the flag to Merck's Keytruda; obesity is several years late and unproven; and the pipeline has suffered repeated Phase III setbacks over the past year. It is a steady cash machine plus a successful turnaround, not an accelerating compounding engine.

Horizontally, its real strengths are global No. 1 diagnostics, a broad pharmaceutical pipeline, and nearly 40 years as a dividend aristocrat. Its weaknesses are structural: lagging immuno-oncology, catch-up obesity, Swiss-franc drag, and a family-governance discount. These strengths are real, but the quality of "growth" is discounted by these structural constraints.

Is the current valuation rewarding past success or borrowing from the future? Neither. It is a fair and slightly conservative price. Forward PE is about 16x, in line with Novartis and far below Eli Lilly. The share price is 27% below the 2022 high, and the 3% dividend provides support. The market is not paying a premium for Roche's growth, nor is it mispricing the company as a declining stock. The market is most likely to misjudge the direction of the obesity option: either too pessimistic, because CT-388 data are competitive and it has entered Phase III, or too optimistic, because a follower will struggle to capture a large profit pool in a winner-take-most obesity field.

Future key variables: over 1 year, whether the strong Swiss franc eases, obesity Phase III data, and old-oncology-drug decline; over 3 years, whether CT-388 can truly enter the top three in obesity and whether China diagnostics pressure bottoms; over 5 years, whether the "diagnostics + treatment" synergy can create another Genentech-level growth engine.

12.1 Bull and Bear Reasons, All Traceable Above

Bull case: 1. Turnaround succeeded: new-drug growth is several times the patent-cliff losses and the group has returned to +7% constant-currency growth (Section III). 2. Deep moat in global No. 1 diagnostics plus integrated diagnostics-treatment synergy (Section V). 3. Fair valuation: about 16x forward PE, in line with Novartis, far below Eli Lilly, and 27% below the high (Sections IV and VII). 4. Nearly 40 years as a dividend aristocrat, 3% dividend support, and strong FCF (Section III). 5. Free obesity option: CT-388 has entered Phase III, with competitive Phase II weight loss of 22.5% after placebo adjustment (Section VIII).

Bear case: 1. Reported growth is structurally eaten by the strong Swiss franc, with Q1 2026 reported down 5% and an 8 pct currency drag on profit (Section III). 2. Oncology franchise erosion: old drugs face biosimilars and immuno-oncology is being crushed by Keytruda (Sections V and VII). 3. Obesity is several years late and unproven: injectable, matching rather than exceeding data, oral tolerability questions, and Eli Lilly/Novo holding 70% of the market (Section VIII). 4. Pipeline setbacks: Phase III failures in giredestrant, astegolimab, and emugrobart (Sections VIII and X). 5. Governance discount: family control of about 65% voting rights with 8.6% economic ownership, and participation certificates have no voting rights (Section V).

12.2 Pre-Mortem: A Script for a 30%+ Loss After 3 Years

Script 1: Obesity disproven plus faster oncology loss. In 2027-2028, CT-388 Phase III data fail to show meaningful differentiation versus tirzepatide/retatrutide, and the market writes the obesity option down to zero. At the same time, Tecentriq/Perjeta and others are further eroded, while Vabysmo faces a counterattack from Eylea HD. Core EPS stalls at CHF 21, and forward PE falls from 16x to 12-13x under a Jefferies-style "premium without growth" narrative. The participation certificate falls to about CHF 250-270, down 16-22% from the current price.

Script 2: Strong Swiss franc plus drug-pricing double hit. The Swiss franc continues to strengthen against the U.S. dollar, keeping reported growth negative for an extended period. At the same time, U.S. MFN concessions and IRA expansion pressure pharmaceutical margins, while USD 50.0 billion of onshore capex weighs on free cash flow. The market rerates Roche as a defensive stock with "zero reported growth and peak margins," compressing forward PE to 12-13x and cutting EPS estimates. The participation certificate falls to about CHF 240-260, down 19-25% from the current price.

The common feature of both scripts: Roche's downside is not a "crash," but a "moderate drift lower plus gradual multiple compression." This is the typical way to lose money in a fair-price stock that lacks a thick safety margin.

12.3 Final Research Conclusion

【Company Profile Scorecard】 Fundamental quality: high | Growth: medium (moderate, offset by currency and erosion) | Moat: strong (diagnostics) / medium (pharmaceuticals changing water) | Financial resilience: strong (no structural leverage problem, strong FCF, dividend aristocrat) | Management credibility: medium-high (smooth transition, rational capital allocation, but family-governance discount) | Valuation attractiveness: medium (fair, neither expensive nor cheap) | Risk level: medium (limited valuation risk, real business-erosion risk) | Suitable investor type: long-term value/defensive investors who prefer certainty, dividends, and option upside.

【Investment Rating】

• Rating: Hold

• One-sentence investment thesis: Roche is a world-class diagnostics-and-treatment twin giant that has survived the patent cliff. Its valuation is fair at about 16x forward PE plus a 3% dividend, but growth is offset by a strong Swiss franc and oncology erosion, the obesity option remains unproven, and the current price lacks a thick safety margin. A lower entry point would be more attractive.

• Three price signals (endpoints from the Section 9.3 valuation scenarios):

Ideal Buy Price: <= CHF 295 (near the upper end of the bear scenario, with about a 15-25% safety margin; the truly attractive range is CHF 250-295)

• Holdable price: CHF 340-385 (the implied value band in the base scenario)

• Clearly overvalued price: >= CHF 520 (above the upper end of the bull scenario)

• Current price classification: below the holdable range / slightly cheap but not materially undervalued (the participation certificate at CHF 322 is below the lower end of the base band of CHF 340, with a mild but not thick safety cushion).

• Is it worth waiting for a better price: yes. Conditions for more active buying: the share price falls below CHF 295 (ideally CHF 250-295), or obesity Phase III / diagnostics inflection validation lifts base-case value. The opportunity cost of waiting is potentially missing +40% in the bull scenario, but downside at the current price (-12% to -22%) and upside (+6% to +19%) are roughly balanced and do not justify chasing.

• Target holding period: 3-5 years, if entered at a reasonable price.

• Expected annualized return (about 3-year holding period, including roughly 3% dividend): bear case about -3% to +1% per year (falling toward the bear band, partly offset by dividends); base case about +5-8% per year (price approaches the base band plus dividends and moderate earnings growth); bull case about +15-20% per year (obesity realized plus rerating).

• Maximum loss risk: Based on the pre-mortem, the worst case is -20% to -25% (obesity disproven + oncology losses + multiple compression), triggered by CT-388 Phase III failure and accelerating oncology share loss.

• Signals that would trigger reassessment: 1. CT-388 Phase III positive and differentiated (upgrade). 2. Core operating margin below 33% for two consecutive quarters (downgrade). 3. Top five growth drugs collectively fall to single-digit constant-currency growth (downgrade). 4. Share price falls below CHF 295 (rating could be upgraded to "Cautious Buy"). 5. A materially weaker Swiss franc turns reported growth positive (upgrade).

Again, this report is based on public information and does not constitute investment advice.

XIII. Key Data Table

Research Uncertainties (Blind Spots)

• Precise current price has source noise and ticker confusion: participation certificates (ROG/ROP) and registered shares (RO) have recently fluctuated in the CHF 311-339 range. After the 2026-03 ticker change, third-party aggregators show ROG/ROPC/ROP side by side with inconsistent as-of dates. This report uses a participation certificate price of about CHF 322 around 2026-06-03. The valuation conclusion is not sensitive to +/-3% price movement, but precise intraday prices should be checked against official SIX data.

• Core and IFRS metrics differ materially: this report uses Roche's core EPS of CHF 19.46 as the main valuation anchor and presents IFRS PE in parallel. PE and margin figures from third-party sites are mostly IFRS-based, and mixing them distorts the analysis.

• The obesity pipeline is the largest uncertainty: whether CT-388/CT-996 can deliver in Phase III and capture meaningful share in a winner-take-most obesity market is a swing factor of roughly one valuation band. At present, it can only be characterized as a discounted option for a late catch-up player.

• Primary annual-report PDF was not checked line by line: detailed items such as the cash-flow statement, segment margins, and drug-by-region breakdowns rely on Roche IR releases plus cross-checks from leading financial/data sources. The annual report PDF was not downloaded for line-by-line verification. Precise segment treatment of ROE and 2025 group FCF should be supplemented from primary sources after drafting.

• Peer valuations are not perfectly comparable across markets and currencies: peer multiples use U.S. stock data as of 2026-06-04, while Roche uses SIX/CHF data from a slightly earlier date. The horizontal comparison is a scale reference, not a precise alignment.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.